Mereo Biopharma Overview

  • Founded
  • 2015
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 35
Employees
  • Latest Deal Type
  • 2ndary - Private
  • Investors
  • 15

Mereo Biopharma General Information

Description

Mereo BioPharma Group PLC is a multi-asset biopharmaceutical company. It is focused on the acquisition, development, and commercialization of innovative therapeutics to improve outcomes for patients with rare and specialty diseases. The company portfolio consists of clinical-stage product candidates that include BPS-804 (setrusumab), AZD-9668 (alvelestat), BGS-649 (leflutrozole), OMP-313M32 (etigilimab), OMP-305B83 (navicixizumab) and BCT-197 (acumapimod).

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • 1 Cavendish Place
  • London W1G 0QF
  • England, United Kingdom
+44 0333 000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Mereo Biopharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Secondary Transaction - Private 15-Mar-2021 00000 Completed Generating Revenue
5. 2PO 12-Feb-2021 00000 00000 Completed Generating Revenue
4. PIPE 03-Jun-2020 000.00 00000 Completed Generating Revenue
3. PIPE 25-Sep-2017 000.00 00000 Completed Clinical Trials - Phase 2
2. IPO 09-Jun-2016 $21.5M $135M 00000 Completed Clinical Trials - Phase 2
1. Early Stage VC 29-Jul-2015 $119M $119M Completed Pre-Clinical Trials
To view Mereo Biopharma’s complete valuation and funding history, request access »

Mereo Biopharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Mereo BioPharma Group PLC is a multi-asset biopharmaceutical company. It is focused on the acquisition, development, and
Drug Discovery
London, United Kingdom
35 As of 2021
00000
00000000000 00000

00000

nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt m
0000000000000
Thousand Oaks, CA
00000 As of 0000
00.000
000000000000 00.000

000000

g elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,
0000 000000000
Bothell, WA
0000 As of 0000
00.000
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mereo Biopharma Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Amgen Formerly PE-Backed Thousand Oaks, CA 00000 00.000 000000000000 00.000
000000 Formerly VC-backed Bothell, WA 0000 00.000 000000000 00.000
000000000 Formerly VC-backed South San Francisco, CA 00000 000.00 00000000000
You’re viewing 3 of 3 competitors. Get the full list »

Mereo Biopharma Patents

Mereo Biopharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210340108-A1 Synthetic method for the preparation of an hydrazine compound Pending 26-Sep-2018 0000000000
AU-2017368155-A1 Methods for treatment of cancer comprising tigit-binding agents Pending 30-Nov-2016 000000000
US-20210101971-A1 Methods for treatment of cancer comprising tigit-binding agents Granted 30-Nov-2016 00000000000
US-11136384-B2 Methods for treatment of cancer comprising tigit-binding agents Active 30-Nov-2016 000000000 000
EP-3548071-A1 Methods for treatment of cancer comprising tigit-binding agents Pending 30-Nov-2016 C07K16/24

Mereo Biopharma Executive Team (8)

Name Title Board Seat Contact Info
Denise Scots-Knight Ph.D Co-Founder, Chief Executive Officer & Board Member
Christine Fox Chief Financial Officer, Finance & Board Member
John Lewicki Ph.D Chief Scientific Officer
John Richard Ph.D Co-Founder & Chief Business Officer
Charles Sermon General Counsel, Legal & Secretary, Administration
You’re viewing 5 of 8 executive team members. Get the full list »

Mereo Biopharma Board Members (13)

Name Representing Role Since
Anders Ekblom Ph.D Self Board Member 000 0000
Brian Schwartz Self Board Member 000 0000
Christine Fox Mereo Biopharma Chief Financial Officer, Finance & Board Member 000 0000
Deepika Pakianathan Ph.D Self Board Member 000 0000
Denise Scots-Knight Ph.D Mereo Biopharma Co-Founder, Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Mereo Biopharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mereo Biopharma Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Schroder UK Public Private Trust Limited Partner Minority 000 0000 000000 0
To view Mereo Biopharma’s complete investors history, request access »

Mereo Biopharma Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000 23-Apr-2019 0000000000 000.00 Drug Discovery 000000 00
Novartis (Mid-Stage Clinical Product Portfolio) 29-Jul-2015 Corporate Asset Purchase Buildings and Property 000000 00
To view Mereo Biopharma’s complete investments and acquisitions history, request access »

Mereo Biopharma Subsidiaries (1)

Company Name Industry Location Founded
0000000 0000000000 Drug Discovery Redwood City, CA 0000
To view Mereo Biopharma’s complete subsidiaries history, request access »